107 related articles for article (PubMed ID: 17952013)
1. Nebivolol induces a hyperpolarizing effect on smooth muscle cells in the mouse renal artery by activation of beta-2-adrenoceptors.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Pharmacology; 2008; 81(2):110-7. PubMed ID: 17952013
[TBL] [Abstract][Full Text] [Related]
2. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
[TBL] [Abstract][Full Text] [Related]
4. Neither K+ channels nor PI3K/Akt mediates the vasodilative effect of nebivolol on different types of rat arteries.
Wang Y; Zhang M; Liu Y; Li J; Song E; Niu L; Cheng N
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):332-8. PubMed ID: 19903983
[TBL] [Abstract][Full Text] [Related]
5. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
6. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
Chlopicki S; Kozlovski VI; Gryglewski RJ
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
[TBL] [Abstract][Full Text] [Related]
7. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
8. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
9. Characterization of nitric oxide release by nebivolol and its metabolites.
Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
[TBL] [Abstract][Full Text] [Related]
10. Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance.
Renna N; Risler N; Cruzado M; Gonzalez S; Lama C; Miatello RM
Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):531-7. PubMed ID: 16309577
[TBL] [Abstract][Full Text] [Related]
11. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
12. Lack of evidence that nebivolol is a β₃-adrenoceptor agonist.
Frazier EP; Michel-Reher MB; van Loenen P; Sand C; Schneider T; Peters SL; Michel MC
Eur J Pharmacol; 2011 Mar; 654(1):86-91. PubMed ID: 21172342
[TBL] [Abstract][Full Text] [Related]
13. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
Ignarro LJ
Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
[TBL] [Abstract][Full Text] [Related]
14. Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum.
Reidenbach C; Schwinger RH; Steinritz D; Kehe K; Thiermann H; Klotz T; Sommer F; Bloch W; Brixius K
Life Sci; 2007 Jun; 80(26):2421-7. PubMed ID: 17512554
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta.
Tran Quang T; Rozec B; Audigane L; Gauthier C
Br J Pharmacol; 2009 Feb; 156(4):601-8. PubMed ID: 19210511
[TBL] [Abstract][Full Text] [Related]
16. Exploring vascular benefits of endothelium-derived nitric oxide.
Cockcroft JR
Am J Hypertens; 2005 Dec; 18(12 Pt 2):177S-183S. PubMed ID: 16373196
[TBL] [Abstract][Full Text] [Related]
17. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol.
Wolf SC; Sauter G; Preyer M; Poerner T; Kempf VA; Risler T; Brehm BR
Cell Physiol Biochem; 2007; 19(1-4):129-36. PubMed ID: 17310107
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta.
de Groot AA; Mathy MJ; van Zwieten PA; Peters SL
J Cardiovasc Pharmacol; 2003 Aug; 42(2):232-6. PubMed ID: 12883327
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms underlying the vasorelaxant action of the pimarane ent-8(14),15-pimaradien-3beta-ol in the isolated rat aorta.
Hipólito UV; Rodrigues GJ; Lunardi CN; Bonaventura D; Ambrosio SR; de Oliveira AM; Bendhack LM; da Costa FB; Tirapelli CR
Eur J Pharmacol; 2009 Aug; 616(1-3):183-91. PubMed ID: 19540222
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of nebivolol on oxygen free radical-induced vasoconstrictions in vitro.
Wagenfeld L; Himpel O; Galambos P; Matthiesen N; Wiermann A; Richard G; Klemm M; Zeitz O
Med Sci Monit; 2008 Jun; 14(6):BR109-112. PubMed ID: 18509268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
